Aperio Group’s ResMed RMD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | $22.8M | Sell |
107,421
-1,857
| -2% | -$370K | 0.07% | 282 |
|
|
2020
Q3 | $18.7M | Sell |
109,278
-1,452
| -1% | -$268K | 0.06% | 291 |
|
|
2020
Q2 | $21.3M | Sell |
110,730
-5,114
| -4% | -$837K | 0.08% | 247 |
|
|
2020
Q1 | $17.1M | Buy |
115,844
+15,138
| +15% | +$2.41M | 0.08% | 260 |
|
|
2019
Q4 | $15.6M | Buy |
100,706
+11,394
| +13% | +$1.64M | 0.06% | 364 |
|
|
2019
Q3 | $12.1M | Buy |
89,312
+6,175
| +7% | +$809K | 0.05% | 427 |
|
|
2019
Q2 | $10.1M | Buy |
83,137
+3,145
| +4% | +$348K | 0.04% | 474 |
|
|
2019
Q1 | $8.32M | Sell |
79,992
-5,327
| -6% | -$550K | 0.04% | 519 |
|
|
2018
Q4 | $9.71M | Buy |
85,319
+19,246
| +29% | +$2.06M | 0.05% | 420 |
|
|
2018
Q3 | $7.62M | Sell |
66,073
-909
| -1% | -$99.6K | 0.03% | 535 |
|
|
2018
Q2 | $6.94M | Buy |
66,982
+17
| +0% | +$1.72K | 0.03% | 555 |
|
|
2018
Q1 | $6.59M | Buy |
66,965
+4,191
| +7% | +$396K | 0.03% | 562 |
|
|
2017
Q4 | $5.32M | Buy |
62,774
+4,863
| +8% | +$402K | 0.03% | 619 |
|
|
2017
Q3 | $4.46M | Hold |
57,911
| – | – | 0.03% | 645 |
|
|
2017
Q2 | $4.51M | Buy |
57,911
+5,949
| +11% | +$426K | 0.03% | 628 |
|
|
2017
Q1 | $3.74M | Buy |
51,962
+1,542
| +3% | +$107K | 0.03% | 659 |
|
|
2016
Q4 | $3.13M | Sell |
50,420
-3,207
| -6% | -$196K | 0.02% | 665 |
|
|
2016
Q3 | $3.47M | Buy |
53,627
+5,327
| +11% | +$355K | 0.03% | 657 |
|
|
2016
Q2 | $3.05M | Buy |
48,300
+13,247
| +38% | +$781K | 0.02% | 666 |
|
|
2016
Q1 | $2.03M | Buy |
35,053
+7,597
| +28% | +$430K | 0.02% | 779 |
|
|
2015
Q4 | $1.47M | Buy |
27,456
+4,563
| +20% | +$257K | 0.01% | 861 |
|
|
2015
Q3 | $1.17M | Buy |
22,893
+1,623
| +8% | +$87.4K | 0.01% | 919 |
|
|
2015
Q2 | $1.2M | Sell |
21,270
-197
| -0.9% | -$12.4K | 0.01% | 898 |
|
|
2015
Q1 | $1.54M | Buy |
21,467
+643
| +3% | +$41.8K | 0.02% | 781 |
|
|
2014
Q4 | $1.17M | Sell |
20,824
-2,874
| -12% | -$150K | 0.01% | 841 |
|
|
2014
Q3 | $1.17M | Buy |
23,698
+595
| +3% | +$30.3K | 0.02% | 796 |
|
|
2014
Q2 | $1.17M | Buy |
23,103
+1,380
| +6% | +$68.4K | 0.02% | 789 |
|
|
2014
Q1 | $971K | Buy |
+21,723
| New | +$976K | 0.01% | 1015 |
|
|
2013
Q4 | – | Sell |
-20,521
| Closed | -$1.04M | – | 935 |
|
|
2013
Q3 | $1.08M | Buy |
20,521
+266
| +1% | +$12.9K | 0.02% | 813 |
|
|
2013
Q2 | $914K | Buy |
+20,255
| New | +$961K | 0.02% | 794 |
|
Other funds holding RMD
Aperio Group's RMD Position: Q4 2020 in Review
Aperio Group reduced its ResMed (RMD) stake by 1.7% in Q4 2020, selling an estimated $370K and leaving 107,421 shares worth $22.8M. The position accounts for 0.07% of the portfolio, ranked #282.
Aperio Group first reported a position in RMD in Q2 2013 and has held it in 30 quarters since. 664 funds tracked by Wall St. Rank hold RMD as of Q4 2020.
- Aperio Group held 107,421 shares of ResMed worth $22.8M as of Q4 2020.
- Aperio Group sold 1,857 ResMed shares in Q4 2020, an estimated $370K.
- ResMed made up 0.07% of Aperio Group's portfolio in Q4 2020, its #282 holding.
- Aperio Group first reported a position in ResMed in Q2 2013 and has held it in 30 quarters since.
- 664 funds tracked by Wall St. Rank held ResMed as of Q4 2020.
Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.